South San Francisco-based Threshold Pharmaceuticals $THLD says that its mid-stage trials for its cancer drug tarloxotinib proved to be a bust, and it’s now restructuring the company as a result. The company – which saw its shares plunge 43% this morning – plans to shift focus to another effort adding evofosfamide to immune checkpoint inhibition. “Stewart M. Kroll, the Company’s Chief Operating Officer, and the members of the biostatistics and data management group will be departing the company,” says the biotech.
Boston-based SQZ, another in a string of spinouts from the lab of MIT’s Bob Langer, has rounded up a $16 million Series B. NanoDimension and Polaris Partners led the round, with participation from other existing and new investors.
Get Endpoints News in your inbox
Newsletters for those who discover, develop, and market drugs. Enjoy the news with the story intact — entire articles in your inbox, no clicks required. Join 12,000+ biopharma pros who read Endpoints News every day. Free subscription.
Subscribe to Endpoints
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.